ECSP22003599A - Profármacos de moduladores del receptor de nmda - Google Patents
Profármacos de moduladores del receptor de nmdaInfo
- Publication number
- ECSP22003599A ECSP22003599A ECSENADI20223599A ECDI202203599A ECSP22003599A EC SP22003599 A ECSP22003599 A EC SP22003599A EC SENADI20223599 A ECSENADI20223599 A EC SENADI20223599A EC DI202203599 A ECDI202203599 A EC DI202203599A EC SP22003599 A ECSP22003599 A EC SP22003599A
- Authority
- EC
- Ecuador
- Prior art keywords
- nmda receptor
- prodrugs
- receptor modulator
- compounds
- depression
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 229940075993 receptor modulator Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a profármacos novedosos de moduladores del receptor de NMDA de fórmula I. Otros aspectos de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y a usos de los compuestos para tratar trastornos neurológicos o trastornos neuropsiquiátricos tales como la depresión.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201900822 | 2019-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22003599A true ECSP22003599A (es) | 2022-02-25 |
Family
ID=71614856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20223599A ECSP22003599A (es) | 2019-07-03 | 2022-01-17 | Profármacos de moduladores del receptor de nmda |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11358971B2 (es) |
| EP (1) | EP3994140A1 (es) |
| JP (1) | JP2022538180A (es) |
| KR (1) | KR20220034052A (es) |
| CN (1) | CN114008053A (es) |
| AR (1) | AR119341A1 (es) |
| AU (1) | AU2020299410A1 (es) |
| BR (1) | BR112021003983A2 (es) |
| CA (1) | CA3144303A1 (es) |
| CL (1) | CL2021003534A1 (es) |
| CO (1) | CO2021017154A2 (es) |
| CR (1) | CR20210663A (es) |
| EC (1) | ECSP22003599A (es) |
| IL (1) | IL289576A (es) |
| JO (1) | JOP20210332A1 (es) |
| MA (1) | MA56450A (es) |
| MX (1) | MX2021015752A (es) |
| PE (1) | PE20220136A1 (es) |
| PH (1) | PH12021553285A1 (es) |
| TW (1) | TW202116780A (es) |
| WO (1) | WO2021001420A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021000297A1 (en) | 2019-07-03 | 2021-01-07 | Merck Sharp & Dohme Corp. | Compounds and methods of use thereof as antibacterial agents |
| US11466027B2 (en) | 2019-07-03 | 2022-10-11 | H. Lundbeck A/S | Modulators of the NMDA receptor |
| US20250212289A1 (en) | 2022-03-18 | 2025-06-26 | Kt Corporation | Method and device for processing application data flow |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026700A (en) | 1989-05-16 | 1991-06-25 | Merrell Dow Pharmaceuticals | Certain quinolines and thienopyridines as excitatory amino acid antagonists |
| US5252581A (en) | 1992-07-20 | 1993-10-12 | Hoechst-Roussel Pharmaceuticals Inc. | Substituted aminothienopyridines, pharmaceutical composition and use |
| US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| PT743853E (pt) | 1994-02-08 | 2001-10-31 | Nps Pharma Inc | Compostos activos num novo local em canis de calcio activados por um receptor uteis para o tratamento de perturbacoes e doencas neurologicas |
| JP2002511835A (ja) | 1996-06-07 | 2002-04-16 | エヌピーエス・ファーマシウティカルズ・インコーポレイテッド | 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物 |
| WO1998056752A1 (en) | 1997-06-11 | 1998-12-17 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| ES2552455T3 (es) * | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CN103298809B (zh) * | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| PL3386591T3 (pl) * | 2015-12-09 | 2021-02-22 | Novartis Ag | Heteroaromatyczne modulatory receptorów nmda i ich zastosowania |
| EP3558318B1 (en) * | 2016-12-22 | 2023-12-20 | Novartis AG | Nmda receptor modulators and uses thereof |
| US11466027B2 (en) | 2019-07-03 | 2022-10-11 | H. Lundbeck A/S | Modulators of the NMDA receptor |
-
2020
- 2020-06-30 US US16/916,681 patent/US11358971B2/en active Active
- 2020-07-01 BR BR112021003983A patent/BR112021003983A2/pt not_active Application Discontinuation
- 2020-07-01 MX MX2021015752A patent/MX2021015752A/es unknown
- 2020-07-01 PE PE2021002224A patent/PE20220136A1/es unknown
- 2020-07-01 MA MA056450A patent/MA56450A/fr unknown
- 2020-07-01 PH PH1/2021/553285A patent/PH12021553285A1/en unknown
- 2020-07-01 CR CR20210663A patent/CR20210663A/es unknown
- 2020-07-01 JP JP2021577276A patent/JP2022538180A/ja active Pending
- 2020-07-01 KR KR1020217042180A patent/KR20220034052A/ko not_active Withdrawn
- 2020-07-01 AU AU2020299410A patent/AU2020299410A1/en not_active Abandoned
- 2020-07-01 CN CN202080045404.6A patent/CN114008053A/zh active Pending
- 2020-07-01 CA CA3144303A patent/CA3144303A1/en active Pending
- 2020-07-01 TW TW109122238A patent/TW202116780A/zh unknown
- 2020-07-01 WO PCT/EP2020/068513 patent/WO2021001420A1/en not_active Ceased
- 2020-07-01 EP EP20740249.6A patent/EP3994140A1/en not_active Withdrawn
- 2020-07-01 JO JOP/2021/0332A patent/JOP20210332A1/ar unknown
- 2020-07-02 AR ARP200101879A patent/AR119341A1/es not_active Application Discontinuation
-
2021
- 2021-12-15 CO CONC2021/0017154A patent/CO2021017154A2/es unknown
- 2021-12-28 CL CL2021003534A patent/CL2021003534A1/es unknown
-
2022
- 2022-01-02 IL IL289576A patent/IL289576A/en unknown
- 2022-01-17 EC ECSENADI20223599A patent/ECSP22003599A/es unknown
- 2022-01-25 US US17/583,333 patent/US20220213117A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022538180A (ja) | 2022-08-31 |
| CR20210663A (es) | 2022-02-22 |
| WO2021001420A1 (en) | 2021-01-07 |
| EP3994140A1 (en) | 2022-05-11 |
| CN114008053A (zh) | 2022-02-01 |
| CL2021003534A1 (es) | 2022-08-19 |
| PE20220136A1 (es) | 2022-01-27 |
| MA56450A (fr) | 2022-05-11 |
| BR112021003983A2 (pt) | 2022-03-15 |
| US11358971B2 (en) | 2022-06-14 |
| IL289576A (en) | 2022-03-01 |
| CA3144303A1 (en) | 2021-01-07 |
| JOP20210332A1 (ar) | 2023-01-30 |
| US20210047342A1 (en) | 2021-02-18 |
| MX2021015752A (es) | 2022-01-27 |
| US20220213117A1 (en) | 2022-07-07 |
| AU2020299410A1 (en) | 2022-02-03 |
| PH12021553285A1 (en) | 2022-08-01 |
| AR119341A1 (es) | 2021-12-09 |
| CO2021017154A2 (es) | 2022-01-17 |
| KR20220034052A (ko) | 2022-03-17 |
| TW202116780A (zh) | 2021-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22003599A (es) | Profármacos de moduladores del receptor de nmda | |
| BR112021021703A2 (pt) | Cicloalquilas substituídas como moduladores da via de estresse integrada | |
| CU20210080A7 (es) | Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| MX2021013193A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| CL2020000422A1 (es) | Composiciones de glp-1 y sus usos. | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| CO2017012545A2 (es) | Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ) | |
| CR20190392A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| DOP2017000117A (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CO2018013240A2 (es) | Oligonucleótidos antisentido para modular la expresión de htra1 | |
| CL2018001210A1 (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico. | |
| CR20180104A (es) | Inhibidores de ezh2 | |
| CR20190393A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| UY36209A (es) | Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen | |
| BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
| ECSP20067907A (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
| ECSP22003596A (es) | Moduladores del receptor de nmda | |
| MX2016010529A (es) | Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6). | |
| MX2019000982A (es) | Compuestos y composiciones y usos de los mismos. | |
| CO2019013317A2 (es) | Oligonucleótidos antisentido para la modulación de la expresión de htra1 | |
| MX2021009519A (es) | Nuevos derivados de n-bencil-2-fenoxibenzamida como moduladores de los receptores de prostaglandina e2 (pge2). | |
| MX2021001335A (es) | Inhibidores de ckd8/19. | |
| MX2020002196A (es) | Moduladores receptores de tipo a de ácido gammaaminobutírico novedosos para trastornos del humor. | |
| DOP2022000026A (es) | Derivados de alcohol como abridores del canal de potasio kv7 |